Randomized trial demonstrates high activity of ponatinib in resistant Philadelphia chromosome-positive leukemias, indicating a viable option against T315I mutations.
Ponatinib was highly active in heavily pretreated patients with Ph-positive leukemias with resistance to tyrosine kinase inhibitors, including patients with the BCR-ABL T315I mutation, other mutations, or no mutations. (Funded by Ariad Pharmaceuticals and others; ClinicalTrials.gov number, NCT00660920.).
No takes yet. Share an insight, caveat, or question.
Cortes et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: